PRE-CONFERENCE WORKSHOPS

Monday, September 26
Afternoon Workshop

Guardant Health

Monday, September 26
Evening Workshop

labcorp

Innovative Liquid Biopsy for Patient Selection & Monitoring

Monday September 26, 2022

12.00pm - 4.00pm

104515

Providing perspectives from biopharma and translational medical centre leaders, this Guardant Health workshop will involve presentations and panel discussions on discovering novel insights from epigenetic (methylation) and genomic data in liquid biopsy for improved patient selection and monitoring.

Do not miss out on uncovering how methylation data can be used to help improve patient stratification for molecular response and accelerate the development of novel therapeutics.

Key Topics:

CDx icon
CDx icon
CDx icon

Improve patient selection by identifying novel predictive or prognostic markers with multi-omic data to differentiate responders and non-responders

Stay ahead of the curve by discovering how epigenetic and genomic content can provide you with a future roadmap for new druggable targets

Learn about Guardant Health's latest technological innovations to improve accuracy in liquid biopsy across the continuum of care and accelerate the next generation of cancer diagnostics

Your Expert Speakers:

Full Agenda & More Details Coming Soon!

When registering, make sure you choose a ticket option that grants access to the Guardant Health Workshop.

This event is reserved for senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch to confirm or decline your place based on the mentioned criteria.

Please Note: This event is taking place in-person only (Boston, MA) and online attendance will not be available.

ABOUT GUARDANT HEALTH:

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, Guardant Reveal™ test for early-stage cancer patients, and Guardant Shield for colorectal cancer screening.

www.guardanthealth.com

Removing the Barriers to Global CDx Development, Regulatory Approval & Commercialization

Monday September 26, 2022

5.00pm - 8.00pm

labcorp

The industry has quickly evolved to adopt biomarker-driven treatment strategies as a foundation of patient care through truly personalized therapeutics. In this session, we will focus on key considerations and components of a successful biomarker strategy from discovery through CDx commercialization, including:

CDx icon
CDx icon
CDx icon
CDx icon

Finding the right patients for your clinical trial to ensure your trial data provides the most meaningful outcomes

Parallel development of your companion diagnostic and therapeutic to ensure there is approval alignment

De-risking access to your diagnostic on day 1 of therapeutic approval to bring the promise of precision medicine to patients in need

Navigating regional regulatory guidelines, engaging unique patient populations and recruiting top-performing investigators to support global commercialization

Expert Speaker List, Full Agenda & More Details Coming Soon!

When registering, make sure you choose a ticket option that grants access to the Labcorp Workshop.

This event is reserved for senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch to confirm or decline your place based on the mentioned criteria.

Please Note: This event is taking place in-person only (Boston, MA) and online attendance will not be available.

ABOUT LABCORP DRUG DEVELOPMENT:

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020.

www.labcorp.com